凋亡通路及药物代谢酶基因多态与吉非替尼治疗的进展期非小细胞肺癌患者疗效及生存的相关研究
|
摘要
第一部分:FAS、FASL和CASP8基因多态与接受吉非替尼治疗的进展期非小细胞肺癌患者疗效及生存的相关研究
表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKI)是局部晚期和转移性非小细胞肺癌患者的重要治疗药物。目前已经发现了一些可预测EGFR TKI疗效的临床病理或生物学指标,如病理类型、性别、吸烟状况、EGFR突变、EGFR基因扩增等,但是这些指标均有一定的局限性。本研究的目的是明确凋亡通路相关基因多态与吉非替尼治疗敏感性及患者生存之间的关系。共入组88例接受吉非替尼单药治疗的ⅢA-Ⅳ期非小细胞肺癌患者,分析临床病理特征以及FAS-1377G/A、FAS-670 A/G、FASL-844T/C、CASP8-652 6N ins/del基因多态与吉非替尼治疗的临床获益率及患者生存的相关性。结果显示腺癌患者临床获益率及总生存期显著优于非腺癌患者(P=0.009和P=0.048);既往治疗的无进展生存期与吉非替尼治疗的临床获益率和无进展生存期显著相关(P=0.003和P=0.001)。本研究首次发现携带FAS-1377 AA基因型的患者接受吉非替尼治疗的临床获益率显著低于携带GG基因型的患者(P=0.008,OR:0.15,95%CI:0.036-0.602)。携带FAS-670 AG+AA基因型的患者总生存期显著优于携带GG基因型的患者(P=0.007)。CASP8-652 6N ins/del基因多态与吉非替尼治疗的无进展生存期相关,携带del遗传变异的患者吉非替尼治疗的无进展生存期显著短于携带ins/ins基因型的患者(P=0.039)。FASL-844T/C基因多态与吉非替尼治疗的临床获益率、无进展生存期及总生存期均无关。多因素预后分析显示病理类型(P=0.020,RR:2.466,95%CI:1.150-5.288)、FAS-670基因多态(P=0.036,RR:0.503,95%CI:0.264-0.955)是独立的预后因素。可见,促进肿瘤细胞凋亡是吉非替尼抗肿瘤作用的重要部分,FAS、CASP8基因多态是吉非替尼治疗敏感性及治疗结局的预测指标。第二部分:CYP1A1基因多态与接受吉非替尼治疗的进展期非小细胞肺癌患者疗效及生存的相关研究
环境和遗传因素均可影响个体对药物的反应。在亚裔人群中进行的许多研究显示CYP1A1基因多态与肺癌的发生风险相关,尤其与不吸烟个体以及鳞癌发生风险的关系更为密切。由于吉非替尼的疗效也与吸烟状况及病理类型相关,且吉非替尼的代谢部分依赖CYP1A1,因此我们对88例接受吉非替尼单药治疗ⅢA-Ⅳ期非小细胞肺癌患者的CYP1A1 m1和m2基因多态进行了研究,并分析这些基因多态与患者疗效和生存的关系。结果显示,全组患者CYP1A1 m1或m2基因多态与吉非替尼治疗的晚期NSCLC患者的临床获益率或生存不相关。但是对于不吸烟患者,CYP1A1 m2 Ile/Ile基因型携带者的2年总生存率为55.7%,Ile/Val+Val/Val基因型携带者的2年总生存率为42.5%,有显著差异(P=0.044),对不吸烟患者进行COX多因素预后分析,发现病理类型(P=0.017,RR:2.958,95%CI:1.215-7.199)、CYP1A1 m1(P=0.016,RR:0.631.95%CI:0.434-0.917)和m2(P=0.001,RR:4.864,95%CI:1.902-12.441)基因多态是独立的预后因素。这些结果提示CYP1A1 m1和m2基因多态可能是接受吉非替尼治疗的晚期、不吸烟NSCLC患者的预后因素。但是由于环境与遗传因素之间、各基因多态之间存在复杂的相互作用,且本研究病例数有限,还需要进一步的研究。
PartⅠ:Association between Polymorphisms in FAS,FASL,CASP8 and the Clinical Outcome in Advanced Non-Small-Cell Lung Cancer Patients Treated with Gefitinib
Epidermal growth factor receptor tyrosine kinase inhibitors play a very important role in the treatment of advanced non-small-cell lung cancer patients.Till now,some clinical and biological predictors have been identified,such as pathological types,sex, smoke,EGFR mutation and EGFR gene copy number,but they all have some limitations.In our study,88 patients with stageⅢA,ⅢB andⅣNSCLC were treated with gefitinib.We investigated the association between polymorphisms in FAS, FASL and CASP8 and the clinical benefit and outcome of these patients.We observed that patients with adenocarcinoma had a significantly higher clinical benefit rate and longer overall survival(P=0.009 and P=0.048,respectively).Longer time from completion of previous chemotherapy were associated with significantly higher clinical benefit rate and longer progression free survival of gefitinib(P=0.003 and P=0.001,respectively).We first documented that FAS-1377 AA genotype carriers had a significantly lower clinical benefit rate compared with GG genotype carriers (P=0.008,OR:0.15,95%CI:0.038-0.614).FAS-670 AG+AA genotype carriers had a significantly longer overall survival time than GG genotype carriers(P=0.007). CASP8-652 6N del/del+del/ins genotype carriers had a significantly shorter progression free survival than ins/ins genotype carriers(P=0.039).After the multi-variants' cox regression analysis,pathological types(P=0.020,RR:2.466, 95%CI:1.150-5.288)and FAS-670 genotype(P=0.036,RR:0.503,95%CI: 0.264-0.955)were found to be independent prognostic factors for these patients.We concluded that polymorphisms in FAS and CASP8 could be predictive or prognostic factors for locally advanced and metastatic NSCLC patients treated with gefitinib.
PartⅡ:Association between Polymorphisms in CYP1A1 and the Clinical Outcome in Advanced Non-Small-Cell Lung Cancer Patients Treated with Gefitinib
The variability in treatment response is due to a lot of environmental and genetic factors.In Asia population,polymorphisms in CYP1A1 have been proved to be associated with lung cancer risk.The CYP1A1 genotype was particularly important at a low level of smoking and in the development of squamous cell carcinoma.Since the benefit from gefitinib was also associated with pathological types and smoking status, and gefitinib was metabolized partly by CYP1A1,we investigated the relationship between polymorphisms in CYP1A1 and the clinical benefit and outcome in 88 advanced non-small-cell lung cancer patients treated with gefitinib.We observed that the polymorphisms in CYP1A1 m1 and m2 were not related to the clinical benefit or outcome of these patients.But the subgroup analysis in non-smoking patients showed that CYP1A1 m2 Ile/Ile genotype carriers had a longer overall survival time than Ile/Val + Val/Val genotype carriers(P=0.044).After the multi-variants' cox regression analysis in non-smoking patients,pathological types(P=0.017,RR:2.958,95%CI: 1.215-7.199) and CYP1A1 ml(P=0.016,RR:0.631,95%CI:0.434-0.917) and m2 (P=0.001,RR:4.864,95%CI:1.902-12.441) genotype were found to be independent prognostic factors.So we concluded that polymorphisms in CYP1A1 may be prognostic factors for non-smoking advaced NSCLC patients treated with gefitnib. But since the sample size was small and the interaction between environmental and genetic factors was complicated,it is necessary to do more research work in this field.
表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKI)是局部晚期和转移性非小细胞肺癌患者的重要治疗药物。目前已经发现了一些可预测EGFR TKI疗效的临床病理或生物学指标,如病理类型、性别、吸烟状况、EGFR突变、EGFR基因扩增等,但是这些指标均有一定的局限性。本研究的目的是明确凋亡通路相关基因多态与吉非替尼治疗敏感性及患者生存之间的关系。共入组88例接受吉非替尼单药治疗的ⅢA-Ⅳ期非小细胞肺癌患者,分析临床病理特征以及FAS-1377G/A、FAS-670 A/G、FASL-844T/C、CASP8-652 6N ins/del基因多态与吉非替尼治疗的临床获益率及患者生存的相关性。结果显示腺癌患者临床获益率及总生存期显著优于非腺癌患者(P=0.009和P=0.048);既往治疗的无进展生存期与吉非替尼治疗的临床获益率和无进展生存期显著相关(P=0.003和P=0.001)。本研究首次发现携带FAS-1377 AA基因型的患者接受吉非替尼治疗的临床获益率显著低于携带GG基因型的患者(P=0.008,OR:0.15,95%CI:0.036-0.602)。携带FAS-670 AG+AA基因型的患者总生存期显著优于携带GG基因型的患者(P=0.007)。CASP8-652 6N ins/del基因多态与吉非替尼治疗的无进展生存期相关,携带del遗传变异的患者吉非替尼治疗的无进展生存期显著短于携带ins/ins基因型的患者(P=0.039)。FASL-844T/C基因多态与吉非替尼治疗的临床获益率、无进展生存期及总生存期均无关。多因素预后分析显示病理类型(P=0.020,RR:2.466,95%CI:1.150-5.288)、FAS-670基因多态(P=0.036,RR:0.503,95%CI:0.264-0.955)是独立的预后因素。可见,促进肿瘤细胞凋亡是吉非替尼抗肿瘤作用的重要部分,FAS、CASP8基因多态是吉非替尼治疗敏感性及治疗结局的预测指标。第二部分:CYP1A1基因多态与接受吉非替尼治疗的进展期非小细胞肺癌患者疗效及生存的相关研究
环境和遗传因素均可影响个体对药物的反应。在亚裔人群中进行的许多研究显示CYP1A1基因多态与肺癌的发生风险相关,尤其与不吸烟个体以及鳞癌发生风险的关系更为密切。由于吉非替尼的疗效也与吸烟状况及病理类型相关,且吉非替尼的代谢部分依赖CYP1A1,因此我们对88例接受吉非替尼单药治疗ⅢA-Ⅳ期非小细胞肺癌患者的CYP1A1 m1和m2基因多态进行了研究,并分析这些基因多态与患者疗效和生存的关系。结果显示,全组患者CYP1A1 m1或m2基因多态与吉非替尼治疗的晚期NSCLC患者的临床获益率或生存不相关。但是对于不吸烟患者,CYP1A1 m2 Ile/Ile基因型携带者的2年总生存率为55.7%,Ile/Val+Val/Val基因型携带者的2年总生存率为42.5%,有显著差异(P=0.044),对不吸烟患者进行COX多因素预后分析,发现病理类型(P=0.017,RR:2.958,95%CI:1.215-7.199)、CYP1A1 m1(P=0.016,RR:0.631.95%CI:0.434-0.917)和m2(P=0.001,RR:4.864,95%CI:1.902-12.441)基因多态是独立的预后因素。这些结果提示CYP1A1 m1和m2基因多态可能是接受吉非替尼治疗的晚期、不吸烟NSCLC患者的预后因素。但是由于环境与遗传因素之间、各基因多态之间存在复杂的相互作用,且本研究病例数有限,还需要进一步的研究。
PartⅠ:Association between Polymorphisms in FAS,FASL,CASP8 and the Clinical Outcome in Advanced Non-Small-Cell Lung Cancer Patients Treated with Gefitinib
Epidermal growth factor receptor tyrosine kinase inhibitors play a very important role in the treatment of advanced non-small-cell lung cancer patients.Till now,some clinical and biological predictors have been identified,such as pathological types,sex, smoke,EGFR mutation and EGFR gene copy number,but they all have some limitations.In our study,88 patients with stageⅢA,ⅢB andⅣNSCLC were treated with gefitinib.We investigated the association between polymorphisms in FAS, FASL and CASP8 and the clinical benefit and outcome of these patients.We observed that patients with adenocarcinoma had a significantly higher clinical benefit rate and longer overall survival(P=0.009 and P=0.048,respectively).Longer time from completion of previous chemotherapy were associated with significantly higher clinical benefit rate and longer progression free survival of gefitinib(P=0.003 and P=0.001,respectively).We first documented that FAS-1377 AA genotype carriers had a significantly lower clinical benefit rate compared with GG genotype carriers (P=0.008,OR:0.15,95%CI:0.038-0.614).FAS-670 AG+AA genotype carriers had a significantly longer overall survival time than GG genotype carriers(P=0.007). CASP8-652 6N del/del+del/ins genotype carriers had a significantly shorter progression free survival than ins/ins genotype carriers(P=0.039).After the multi-variants' cox regression analysis,pathological types(P=0.020,RR:2.466, 95%CI:1.150-5.288)and FAS-670 genotype(P=0.036,RR:0.503,95%CI: 0.264-0.955)were found to be independent prognostic factors for these patients.We concluded that polymorphisms in FAS and CASP8 could be predictive or prognostic factors for locally advanced and metastatic NSCLC patients treated with gefitinib.
PartⅡ:Association between Polymorphisms in CYP1A1 and the Clinical Outcome in Advanced Non-Small-Cell Lung Cancer Patients Treated with Gefitinib
The variability in treatment response is due to a lot of environmental and genetic factors.In Asia population,polymorphisms in CYP1A1 have been proved to be associated with lung cancer risk.The CYP1A1 genotype was particularly important at a low level of smoking and in the development of squamous cell carcinoma.Since the benefit from gefitinib was also associated with pathological types and smoking status, and gefitinib was metabolized partly by CYP1A1,we investigated the relationship between polymorphisms in CYP1A1 and the clinical benefit and outcome in 88 advanced non-small-cell lung cancer patients treated with gefitinib.We observed that the polymorphisms in CYP1A1 m1 and m2 were not related to the clinical benefit or outcome of these patients.But the subgroup analysis in non-smoking patients showed that CYP1A1 m2 Ile/Ile genotype carriers had a longer overall survival time than Ile/Val + Val/Val genotype carriers(P=0.044).After the multi-variants' cox regression analysis in non-smoking patients,pathological types(P=0.017,RR:2.958,95%CI: 1.215-7.199) and CYP1A1 ml(P=0.016,RR:0.631,95%CI:0.434-0.917) and m2 (P=0.001,RR:4.864,95%CI:1.902-12.441) genotype were found to be independent prognostic factors.So we concluded that polymorphisms in CYP1A1 may be prognostic factors for non-smoking advaced NSCLC patients treated with gefitnib. But since the sample size was small and the interaction between environmental and genetic factors was complicated,it is necessary to do more research work in this field.
引文
Alexandrie AK,Warholm M,Carstensen U,Axmon A,Hagmar L,Levin JO,Ostman C,Rannug A.(2000)CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure.Carcinogenesis.21:669-676.
Arteaga CL.(2002)Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.Semin Oncol.29:3-9.
Bailey R,Kris M,Wolf M.(2003)Gefitinib(Iressa,ZD1839)monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2:tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone.Lung Cancer.41:S71.
Bartsch H,Nair U,Risch A,Rojas M,Wikman H,Alexandrov K.(2000)Genetic polymorphism of CYP genes,alone or in combination,as a risk modifier of tobacco-related cancers.Cancer Epidemiol Biomarkers Prev.9:3-28.
Bell DW,Lynch TJ,Haserlat SM,Harris PL,Okimoto RA,Brannigan BW,Sgroi DC,Muir B,Riemenschneider MJ,Iacona RB,Krebs AD,Johnson DH,Giaccone G,Herbst RS,Manegold C,Fukuoka M,Kris MG,Baselga J,Ochs JS,Haber DA.(2005)Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer:Molecular analysis of the IDEAL/INTACT gefitinib trials.J Clin Oncol.23:8081-8092.
Bouchardy C,Wikman H,Benhamou S.(1997)CYP1A1 genetic polymorphisms,tobacco smoking and lung cancer risk in a French Caucasian population.Biomarkers.2:131-134.
Cappuzzo F,Gregorc V,Rossi E,Cancellieri A,Magrini E,Paties CT,Ceresoli G,Lombardo L,Bartolini S,Calandri C,de Rosa M,Villa E,Crino L.(2003)Gefitinib in pretreated non-small-cell lung cancer(NSCLC):Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.J Clin Oncol.21:2658-2663.
Cappuzzo F,Hirsch FR,Rossi E,Bartolini S,Ceresoli GL,Bemis L,Haney J,Witta S,Danenberg K,Domenichini I,Ludovini V,Magrini E,Gregorc V,Doglioni C,Sidoni A,Tonato M,Franklin WA,Crino L,Bunn PA Jr,Varella-Garcia M.(2005a)Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer.J Natl Cancer Inst.97:643-655 ?
Cappuzzo F,Varella-Garcia M,Shigematsu H,Domenichini I,Bartolini S,Ceresoli GL,Rossi E,Ludovini V,Gregorc V,Toschi L,Franklin WA,Crino L,Gazdar AF,Bunn PA Jr,Hirsch FR.(2005b)Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.J Clin Oncol.23:5007-5018.
Cappuzzo F,Toschi L,Domenichini I,Bartolini S,Ceresoli GL,Rossi E,Ludovini V,Cancellieri A,Magrini E,Bemis L,Franklin WA,Crino L,Bunn PA Jr,Hirsch FR,Varella-Garcia M.(2005c)HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.Br J Cancer.93:1334-1340.
Chang GC,Hsu SL,Tsai JR,Liang FP,Lin SY,Sheu GT,Chen CY.(2004)Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.Biochem Pharmacol.68:1453-1464.
Chen YM,Perng RP,Tsai CM.(2005)Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan:a prospective phase Ⅱ study.J Chemother.17:679-684.
Eberhard DA,Johnson BE,Amler LC,Goddard AD,Heldens SL,Herbst RS,Ince WL,J(a|¨)nne PA,Januario T,Johnson DH,Klein P,Miller VA,Ostland MA,Ramies DA,Sebisanovic D,Stinson JA,Zhang YR,Seshagiri S,Hillan KJ.(2005)Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol.23:5900-5909.
Efferth T,Volm M.(2005)Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther.107:155-176.
Engels EA,Wu X,Gu J,Dong Q,Liu J,Spitz MR.(2007)Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer.Cancer Res.67:6520-6527.
Evans WE,Relling MV.(2004)Moving towards individualized medicine with pharmacogenomics.Nature.429:464-468.
Evan GI,Vousden KH.(2001)Proliferation,cell cycle and apoptosis in cancer.Nature.411:342-348.
Fukuoka M,Yano S,Giaccone G,Tamura T,Nakagawa K,Douillard JY,Nishiwaki Y,Vansteenkiste J,Kudoh S,Rischin D,Eek R,Horai T,Noda K,Takata I,Smit E,Averbuch S,Macleod A,Feyereislova A,Dong RP,Baselga J.(2003)Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J Clin Oncol.21:2237-2246.
Garcia-Closas M,Kelsey KT,Wiencke JK,Xu X,Wain JC,Christiani DC.(1997)A case-control study of cytochrome P450 1A1,glutathione S-transferase Ml,cigarette smoking and lung cancer susceptibility(Massachusetts,United States).Cancer Causes Control.8:544-553.
Gatzemeier U,Heller A,Foernzler D.(2005)Exploratory analyses EGFR,kRAS mutations and other molecular markers in tumors of NSCLC patients(pts)treated with chemotherapy±erlotinib(TALENT).J Clin Oncol.23:16s:7028a.
Gervasini G,Garc(?)a-Mart(?)n E,Ladero JM,Pizarro R,Sastre J,Martinez C,Garc(?)a M,Diaz-Rubio M,Ag(?)ndez JA.(2007)Genetic variability in CYP3A4 and CYP3A5 in primary liver,gastric and colorectal cancer patients.BMC Cancer.2:118-125.
Guan ZZ,Zhang L,Li LY,Jiang GL,Liu XY,Chu DT,Zhao HY,Li W.(2005)Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small-cell lung cancer:a clinical trial.Ai Zheng.24:980-984.
Guidance for Industry Pharmacogenomic Data Submissions[http://www.fda.gov /cder /guidance /6400fhl.pdf]
Hajra KM,Liu JR.(2004)Apoptosome dysfunction in human cancer.Apoptosis.9:691-704.
Hirsch FR,Varella-Garcia M,Bunn PA Jr,Franklin WA,Dziadziuszko R,Thatcher N,Chang A,Parikh P,Pereira JR,Ciuleanu T,von Pawel J,Watkins C,Flannery A,Ellison G,Donald E,Knight L,Parums D,Botwood N,Holloway B.(2006)Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small cell lung cancer.J Clin Oncol.24:5034-5042.
Hirvonen A,Husgafvel-Pursiainen K,Anttila S,Karjalainen A,Sorsa M,Vainio H.(1992)Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.Pharmacogenetics.2:259-263.
Ho PK,Hawkins CJ.(2005)Mammalian initiator apoptotic caspases.FEBS J.272:5436-5453.
Huang QR,Morris D,Manolios N.(1997)Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas(CD95)gene.Mol Immunol.34:577-582.
Hung RJ,Boffetta P,Brockmoller J,Butkiewicz D,Cascorbi I,Clapper ML,Garte S,Haugen A,Hirvonen A,Anttila S,Kalina I,Le Marchand L,London SJ,Rannug A,Romkes M,Salagovic J,Schoket B,Gaspari L,Taioli E.(2003)CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers:a pooled analysis.Carcinogenesis.24:875-882.
Inoue A,Suzuki T,Fukuhara T,Maemondo M,Kimura Y,Morikawa N,Watanabe H,Saijo Y,Nukiwa T.(2006)Prospective phase Ⅱ study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.J Clin Oncol.24:3340-3346.
Jackman DM,Yeap BY,Sequist LV,Lindeman N,Holmes AJ,Joshi VA,Bell DW,Huberman MS,Halmos B,Rabin MS,Haber DA,Lynch TJ,Meyerson M, Johnson BE,J(a|¨)nne PA.(2006)Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res.12:3908-3914.
Jiang H.(2009)Overview of gefitinib in non-small cell lung cancer:an asian perspective.Jpn J Clin Oncol.39:137-150.
Kakiuchi S,Daigo Y,Ishikawa N,Furukawa C,Tsunoda T,Yano S,Nakagawa K,Tsuruo T,Kohno N,Fukuoka M,Sone S,Nakamura Y.(2004)Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib(Iressa,ZD1839).Hum Mol Genet.13:3029-3043.
Kawajiri K,Nakachi K,Imai K,Yoshii A,Shinoda N,Watanabe J.(1990)Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene.FEBS Lett.263:131-133.
Kelly K,Crowley J,Bunn PA Jr,Presant CA,Grevstad PK,Moinpour CM,Ramsey SD,Wozniak AJ,Weiss GR,Moore DF,Israel VK,Livingston RB,Gandara DR.(2001)Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a Southwest Oncology Group trial.J Clin Oncol.19:3210-3218.
Kiechle FL,Zhang X.(2002)Apoptosis:biochemical aspects and clinical implications.Clin Chim Acta.326:27-45.
Kim JG,Chae YS,Sohn SK,Moon JH,Ryoo HM,Bae SH,Kum Y,Jeon SW,Lim KH,Kang BM,Park IJ,Choi GS,Jun SH.(2009)Prostaglandin synthase 2/cyclooxygenase 2(PTGS2/COX2)8473T＞C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.Cancer Chemother Pharmacol.Feb 15.
Kim ES,Hirsch V,Mok T,Socinski MA,Gervais R,Wu YL,Li LY,Watkins CL,Sellers MV,Lowe ES,Sun Y,Liao ML,Osterlind K,Reck M,Armour AA,Shepherd FA,Lippman SM,Douillard JY.(2008)Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase Ⅲ trial.Lancet.372:1809-1818.
Koomagi R,Volm M.(1999)Expression of FAS(CD95/APO-1)and FAS ligand in lung cancer,its prognostic and predictive relevance.Int J Cancer.84:239-243.
Kris MG,Natale RB,Herbst RS,Lynch TJ Jr,Prager D,Belani CP,Schiller JH,Kelly K,Spiridonidis H,Sandler A,Albain KS,Cella D,Wolf MK,Averbuch SD,Ochs JJ,Kay AC.(2003)Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer.A randomized trial.J Am Med Assoc.290:2149-2158.
Landi MT,Bertazzi PA,Shields PG,Clark G,Lucier GW,Garte SJ,Cosma G,Caporaso NE.(1994)Association between CYP1A1 genotype,mRNA expression and enzymatic activity in humans.Pharmacogenetics.4:242-246.
Lee D,Kim S,Park K,Kim J,Lee J,Shin S,Kang J,Suh C,Ahn M,Ahn J.(2008)A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer(NSCLC)who have previously received platinum-based chemotherapy.J Clin Oncol.26(Suppl)(abstr 8025).
Lenferink AE,Pinkas-Kramarski R,van de Poll ML,van Vugt MJ,Klapper LN,Tzahar E,Waterman H,Sela M,van Zoelen EJ,Yarden Y.(1998)Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.EMBO J.17:3385-3397.
Li J,Zhao M,He P,Hidalgo M,Baker SD.(2007)Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes.Clin Cancer Res.13:3731-3737.
Ling YH,Lin R,Perez-Soler R.(2008)Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.Mol Pharmacol. 74:793-806.
刘炬,张雪梅,张湘茹,袁芃、徐兵河、林东昕。(2006)ERCC6 C6530G 单核苷酸多态与局限期小细胞肺癌患者生存相关。中国癌症杂志。16:943-947。
Loukola A,Chadha M,Penn SG,Rank D,Conti DV,Thompson D,Cicek M,Love B,Bivolarevic V,Yang Q,Jiang Y,Hanzel DK,Dains K,Paris PL,Casey G,Witte JS.(2004) Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1,CYP3A4,and SRD5A2.Eur J Hum Genet.12:321-332.
Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC,Settleman J,Haber DA.(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med.350:2129-2139.
Ma F,Sun T,Shi Y,Yu D,Tan W,Yang M,Wu C,Chu D,Sun Y,Xu B,Lin D.(2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.Lung Cancer,2009,Feb 5.
Marchetti A,Felicioni L,Buttitta F.(2006) Assessing EGFR mutations.N Engl J Med.354:526-528.
Maruyama R,Nishiwaki Y,Tamura T,Yamamoto N,Tsuboi M,Nakagawa K,Shinkai T,Negoro S,Imamura F,Eguchi K,Takeda K,Inoue A,Tomii K,Harada M,Masuda N,Jiang H,Itoh Y,Ichinose Y,Saijo N,Fukuoka M.(2008) Phase Ⅲstudy,V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.J Clin Oncol.26:4244-4252.
Masson LF,Sharp L,Cotton SC,Little J.(2005) Cytochrome P450 1A1 gene polymorphisms and risk of breast cancer:A HuGE review.Am J Epidemiol.161:901-915.
Mendelsohn J,Baselga J.(2000)The EGF receptor family as targets for cancer therapy.Oncogene.19:6550-6565.
Miller VA,Zakowski M,Riley GJ,Pao W,Ladanyi M,Tsao AS,Sandler A,Herbst R,Kris MG,Johnson DH.(2006)EGFR mutation and copy number,EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma(BAC):results of a prospective phase Ⅱ trial.J Clin Oncol.24:364s.
Mok T,Wu YL,Thongprasert S.(2008)Phase Ⅲ,randomised,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer.Ann Oncol.19(Suppl.8)(viiil,Abstract LBA2).
Mooney LV,Bell DA,Santella RM,Van Bennekum AM,Ottman R,Paik M,Blaner WS,Lucier GW,Covey L,Young TL,Cooper TB,Glassman AH,Perera FP.(1997)Contribution of genetic and nutritional factors to DNA damage in heavy smokers.Carcinogenesis.18:503-509.
Morita S,Hiroshima T,Hagiwara K.(2008)I-CAMP Study Group.Gefitinib combined survival analysis of the mutation positives from the prospective phase Ⅱ trials(I-CAMP).J Clin Oncol.6(Suppl.)(Abstract 8101).
Nambu Y,Hughes SJ,Rehemtulla A.(1998)Lack of cell surface FAS/APO-1 expression in pulmonary adenocarcinoma.J Clin Invest.101:1102-1110.
Normanno N,Campiglio M,De LA,Hamstra D,Orringer MB,Beer DG.(2002)Cooperative inhibitory effect of ZD1839(Iressa)in combination with trastuzumab(Herceptin)on human breast cancer cell growth.Ann Oncol.13:65-72.
Paez JG,Janne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H,FujⅡ Y,Eck MJ,Sellers WR,Johnson BE,Meyerson M.(2004)EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy.Science.304:1497-1500.
Pan JH,Han JX,Wu JM,Sheng LJ,Huang HN.(2007)CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.Acta Oncol.46:361-366.
Pao W,Wang TY,Riely GJ,Miller VA,Pan Q,Ladanyi M,Zakowski MF,Heelan RT,Kris MG,Varmus HE.(2005)KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PLoS Med.2:el 7.
Park JY,Lee WK,Jung DK,Choi JE,Park TI,Lee EB,Cho S,Park JY,Cha SI,Kim CH,Kam S,Jung TH,Jheon S.(2009)Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.Clin Cancer Res.15:1794-1800.
Parkin DM,Bray F,Ferlay J,Pisani P.(2005)Global cancer statistics,2002.CA Cancer J Clin.55:74-108.
Park K,Goto K.(2006)A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.Curr Med Res Opin.22:561-573.
Paz-Ares L,Sanchez JM,Garci'a-Velasco A,Massuti B,Lopez-Vivanco G,Provencio M,Montes A,Isla D,Amador ML,Rosell R,Spanish Lung Cancer Group.(2006)A prospective phase Ⅱ trial of erlotinib in advanced non-small cell lung cancer(NSCLC)patients(p)with mutations in the tyrosine kinase(TK)domain of the epidermal growth factor receptor(EGFR).J Clin Oncol,24(suppl):18s:7020a.
Perez-Soler R,Chachoua A,Hammond LA,Rowinsky EK,Huberman M,Karp D,Rigas J,Clark GM,Santabarbara P,Bonomi P.(2004)Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol.22:3238-3247.
Pham D,Kris MG,Riely GJ,Sarkaria IS,McDonough T,Chuai S,Venkatraman ES,
Miller VA,Ladanyi M,Pao W,Wilson RK,Singh B,Rusch VW.(2006)Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.J Clin Oncol.24:1700-1704 。
Piechocki MP,Yoo GH,Dibbley SK,Amjad EH,Lonardo F.(2006)Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.Int J Cancer.119:441-454.
Pirker R,Szczesna A,von Pawel J,Krzakowski M,Ramlau R,Park K,Gatzemeier U,Bajeta E,Emig M,Pereira JR.(2008)FLEX:A randomized multicenter,phase Ⅲ study of cetuximab in combination with cisplatin/vinorelbine(CV)versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer(NSCLC).J Clin Oncol.26:3
Raff M.(1998)Cell suicide for beginners.Nature.396:119-122.
Reed JC.(2000)Mechanisms of apoptosis.Am J Pathol.157:1415-1430.
Rho JK,Choi YJ,Ryoo BY,Na Ⅱ,Yang SH,Kim CH,Lee JC.(2007)p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.Cancer Res.67:1163-1169.
Riely GJ,Pao W,Pham D,Li AR,Rizvi N,Venkatraman ES,Zakowski MF,Kris MG,Ladanyi M,Miller VA.(2006)Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res.12:839-844.
Risch NJ.(2000)Searching for genetic determinants in the new millennium.Nature.405:847-856.
Sanchez-Cespedes M,Ahrendt SA,Piantadosi S,Rosell R,Monzo M,Wu L,Westra WH,Yang SC,Jen J,Sidransky D.(2001)Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.Cancer Res.61:1309-1313.
Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R, Johnson DH.(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med.355:2542-2550.
Sasaki H,Endo K,Takada M,Kawahara M,Tanaka H,Kitahara N,Matsumura A,Iuchi K,Kawaguchi T,Okuda K,Kawano O,Yukiue H,Yokoyama T,Yano M,Fujii Y.(2008)EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer.J Surg Res.148:260-263.
Schiller JH,Harrington D,Belani CP,Langer C,Sandler A,Krook J,Zhu J,Johnson DH;Eastern Cooperative Oncology Group.(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med.346:92-98.
Sequist LV,Joshi VA,Janne PA,Muzikansky A,Fidias P,Meyerson M,Haber DA,Kucherlapati R,Johnson BE,Lynch TJ.(2001)Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist.12:90-98.
Sequist LV,Martins RG,Spigel D,Grunberg SM,Spira A,Janne PA,Joshi VA,McCollum D,Evans TL,Muzikansky A,Kuhlmann GL,Han M,Goldberg JS,Settleman J,Iafrate AJ,Engelman JA,Haber DA,Johnson BE,Lynch TJ.(2008)First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations.J Clin Oncol.26:2442-2449.
Shigematsu H,Lin L,Takahashi T,Nomura M,Suzuki M,Wistuba Ⅱ,Fong KM,Lee H,Toyooka S,Shimizu N,Fujisawa T,Feng Z,Roth JA,Herz J,Minna JD,Gazdar AF.(2005)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst.97:339-346.
Smart J,Daly AK.(2000)Variation in induced CYPlAl levels:relationship to CYPlAl,Ah receptor and GSTM1 polymorphisms.Pharmacogenetics.10:11-24.
Song N,Tan W,Xing D,Lin D.(2001)CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking:a case-control study in China.Carcinogenesis.22:11-16.
Sugimura H,Wakai K,Genka K,Nagura K,Igarashi H,Nagayama K,Ohkawa A,Baba S,Morris BJ,Tsugane S,Ohno Y,Gao C,Li Z,Takezaki T,Tajima K,Iwamasa T.(1998)Association of Ile462Val(Exon 7)polymorphism of cytochrome P450 IAI with lung cancer in the Asian population:further evidence from a case-control study in Okinawa.Cancer Epidemiol Biomarkers Prev.7:413-417.
Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels[http://www.fda.gov:80/cder/genomics/ genomic_biomarkers_table.htm]
Taioli E,Gaspari L,Benhamou S,Boffetta P,Brockmoller J,Butkiewicz D,Cascorbi I,Clapper ML,Dolzan V,Haugen A,Hirvonen A,Husgafvel-Pursiainen K,Kalina I,Kremers P,Le Marchand L,London S,Rannug A,Romkes M,Schoket B,Seidegard J,Strange RC,Stucker I,To-Figueras J,Garte S.(2003)Polymorphisms in CYP1A1,GSTM1,GSTT1 and lung cancer below the age of 45 years.Int J Epidemiol.32:60-63.
Takano T,Ohe Y,Sakamoto H,Tsuta K,Matsuno Y,Tateishi U,Yamamoto S,Nokihara H,Yamamoto N,Sekine I,Kunitoh H,Shibata T,Sakiyama T,Yoshida T,Tamura T.(2005)Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.J Clin Oncol.23:6829-6837.
Tefre T,Ryberg D,Haugen A.(1991)Human CYP1A1(cytochrome P(1)450)gene:lack of association between the Mspl restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population.Pharmacogenetics.1:20-25.
Thatcher N,Chang A,Parikh P,Rodrigues Pereira J,Ciuleanu T,von Pawel J,Thongprasert S,Tan EH,Pemberton K,Archer V,Carroll K.(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer).Lancet.366:1527-1537.
Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG.(2000)New guidelines to evaluate the response to treatment in solid tumors.EuropeanOrganization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst.92:205-216.
Tsao M,Zhu C,Sakurada A,Zhang T,Whitehead M,Kamel-Reid S,Ding K,Seymour L,Shepherd F.(2006)An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer.J Clin Oncol.24:365s.
Tsao MS,Sakurada A,Cutz JC,Zhu CQ,Kamel-Reid S,Squire J,Lorimer I,Zhang T,Liu N,Daneshmand M,Marrano P,da Cunha Santos G,Lagarde A,Richardson F,Seymour L,Whitehead M,Ding K,Pater J,Shepherd FA.(2005)Erlotinib in lung cancer-molecular and clinical predictors of outcome.N Engl J Med.353:133-144.
Villaflor VM,Buckingham L,Gale M,Coon J,Mauer AM,Muzzafar T,Kaiser K,Shannon M,Morrison L,Bonomi P.(2006)EGFR mutations(muts),IHC and FISH status,and chromosome 7 gene copy number combined with pAkt expression as potential predictors of survival in non-small cell lung cancer(NSCLC)patients(pts)treated with gefitinib(GEF).J Clin Oncol.24:18s:7182a0
Vineis P,Bartsch H,Caporaso N,Harrington AM,Kadlubar FF,Landi MT,Malaveille C,Shields PQ Skipper P,Talaska G,et al.(1994)Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens.Nature.369:154-156.
Vineis P.(1997)Molecular epidemiology:low-dose carcinogens and genetic susceptibility.Int J Cancer.71:1-3.
Vineis R Veglia F,Benhamou S,Butkiewicz D,Cascorbi I,Clapper ML,Dolzan V,Haugen A,Hirvonen A,Ingelman-Sundberg M,Kihara M,Kiyohara C,Kremers P,Le Marchand L,Ohshima S,Pastorelli R,Rannug A,Romkes M,Schoket B,Shields P,Strange RC,Stucker I,Sugimura H,Garte S,Gaspari L,Taioli E.(2003)CYP1A1 T3801 C polymorphism and lung cancer:a pooled analysis of 2451 cases and 3358 controls.Int J Cancer.104:650-657.
Volm M,Koomagi R.(2008)Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.Br J Cancer.82:1747-1754.
Wang SE,Narasanna A,Perez-Torres M,Xiang B,Wu FY,Yang S,Carpenter G,Gazdar AF,Muthuswamy SK,Arteaga CL.(2006)HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Cancer Cell.10:25-38.
Whyatt RM,Bell DA,Jedrychowski W,Santella RM,Garte SJ,Cosma G,Manchester DK,Young TL,Cooper TB,Ottman R,Perera FP.(1998)Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype.Carcinogenesis.19:1389-1392.
Wilkinson GR.(2005)Drug metabolism and variability among patients in drug response.N Engl J Med.352:2211-2221.
Woodburn JR.(1999)The epidermal growth factor receptor and its inhibition in cancer therapy.Pharmacol Ther.82:241-250.
Wu J,Metz C,Xu X,Abe R,Gibson AW,Edberg JC,Cooke J,Xie F,Cooper GS,Kimberly RP.(2003)A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression:a candidate background gene in African American systemic lupus erythematosus patients.J Immunol.170:132-138.
Yang CH,Yu CJ,Shih JY,Chang YC,Hu FC,Tsai MC,Chen KY,Lin ZZ,Huang CJ,Shun CT,Huang CL,Bean J,Cheng AL,Pao W,Yang PC.(2008)Specific EGFR mutations predict treatment outcome of stage ⅢB/Ⅳ patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.J Clin Oncol.26:2745-2753.
Yang M,Sun T,Wang L,Yu D,Zhang X,Miao X,Liu J,Zhao D,Li H,Tan W,Lin D.(2008)Functional variants in cell death pathway genes and risk of pancreatic cancer.Clin Cancer Res.14:3230-3236.
Yoon KA,Park S,Hwangbo B,Shin HD,Cheong HS,Shin HR,Lee JS.(2007)Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.Carcinogenesis.28:1971-1977.
Zhang B,Sun T,Xue L,Han X,Zhang B,Lu N,Shi Y,Tan W,Zhou Y,Zhao D,Zhang X,Guo Y,Lin D.(2007)Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.Carcinogenesis.28:1067-1073.
Zhang X,Miao X,Sun T,Tan W,Qu S,Xiong P,Zhou Y,Lin D.(2005)Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.J Med Genet.42:479-484.
Zhou BB,Peyton M,He B,Liu C,Girard L,Caudler E,Lo Y,Baribaud F,Mikami I,Reguart N,Yang G,Li Y,Yao W,Vaddi K,Gazdar AF,Friedman SM,Jablons DM,Newton RC,Fridman JS,Minna JD,Scherle PA.(2006)Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.Cancer Cell.10:39-50.
Zimmerman KC,Bonzon C,Green DR.(2002)The machinery of programmed cell death.Pharmacol Ther.92:57-70.
Arteaga CL.(2002)Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.Semin Oncol.29:3-9.
Bailey R,Kris M,Wolf M.(2003)Gefitinib(Iressa,ZD1839)monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2:tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone.Lung Cancer.41:S71.
Bartsch H,Nair U,Risch A,Rojas M,Wikman H,Alexandrov K.(2000)Genetic polymorphism of CYP genes,alone or in combination,as a risk modifier of tobacco-related cancers.Cancer Epidemiol Biomarkers Prev.9:3-28.
Bell DW,Lynch TJ,Haserlat SM,Harris PL,Okimoto RA,Brannigan BW,Sgroi DC,Muir B,Riemenschneider MJ,Iacona RB,Krebs AD,Johnson DH,Giaccone G,Herbst RS,Manegold C,Fukuoka M,Kris MG,Baselga J,Ochs JS,Haber DA.(2005)Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer:Molecular analysis of the IDEAL/INTACT gefitinib trials.J Clin Oncol.23:8081-8092.
Bouchardy C,Wikman H,Benhamou S.(1997)CYP1A1 genetic polymorphisms,tobacco smoking and lung cancer risk in a French Caucasian population.Biomarkers.2:131-134.
Cappuzzo F,Gregorc V,Rossi E,Cancellieri A,Magrini E,Paties CT,Ceresoli G,Lombardo L,Bartolini S,Calandri C,de Rosa M,Villa E,Crino L.(2003)Gefitinib in pretreated non-small-cell lung cancer(NSCLC):Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.J Clin Oncol.21:2658-2663.
Cappuzzo F,Hirsch FR,Rossi E,Bartolini S,Ceresoli GL,Bemis L,Haney J,Witta S,Danenberg K,Domenichini I,Ludovini V,Magrini E,Gregorc V,Doglioni C,Sidoni A,Tonato M,Franklin WA,Crino L,Bunn PA Jr,Varella-Garcia M.(2005a)Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer.J Natl Cancer Inst.97:643-655 ?
Cappuzzo F,Varella-Garcia M,Shigematsu H,Domenichini I,Bartolini S,Ceresoli GL,Rossi E,Ludovini V,Gregorc V,Toschi L,Franklin WA,Crino L,Gazdar AF,Bunn PA Jr,Hirsch FR.(2005b)Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.J Clin Oncol.23:5007-5018.
Cappuzzo F,Toschi L,Domenichini I,Bartolini S,Ceresoli GL,Rossi E,Ludovini V,Cancellieri A,Magrini E,Bemis L,Franklin WA,Crino L,Bunn PA Jr,Hirsch FR,Varella-Garcia M.(2005c)HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.Br J Cancer.93:1334-1340.
Chang GC,Hsu SL,Tsai JR,Liang FP,Lin SY,Sheu GT,Chen CY.(2004)Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.Biochem Pharmacol.68:1453-1464.
Chen YM,Perng RP,Tsai CM.(2005)Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan:a prospective phase Ⅱ study.J Chemother.17:679-684.
Eberhard DA,Johnson BE,Amler LC,Goddard AD,Heldens SL,Herbst RS,Ince WL,J(a|¨)nne PA,Januario T,Johnson DH,Klein P,Miller VA,Ostland MA,Ramies DA,Sebisanovic D,Stinson JA,Zhang YR,Seshagiri S,Hillan KJ.(2005)Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol.23:5900-5909.
Efferth T,Volm M.(2005)Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther.107:155-176.
Engels EA,Wu X,Gu J,Dong Q,Liu J,Spitz MR.(2007)Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer.Cancer Res.67:6520-6527.
Evans WE,Relling MV.(2004)Moving towards individualized medicine with pharmacogenomics.Nature.429:464-468.
Evan GI,Vousden KH.(2001)Proliferation,cell cycle and apoptosis in cancer.Nature.411:342-348.
Fukuoka M,Yano S,Giaccone G,Tamura T,Nakagawa K,Douillard JY,Nishiwaki Y,Vansteenkiste J,Kudoh S,Rischin D,Eek R,Horai T,Noda K,Takata I,Smit E,Averbuch S,Macleod A,Feyereislova A,Dong RP,Baselga J.(2003)Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J Clin Oncol.21:2237-2246.
Garcia-Closas M,Kelsey KT,Wiencke JK,Xu X,Wain JC,Christiani DC.(1997)A case-control study of cytochrome P450 1A1,glutathione S-transferase Ml,cigarette smoking and lung cancer susceptibility(Massachusetts,United States).Cancer Causes Control.8:544-553.
Gatzemeier U,Heller A,Foernzler D.(2005)Exploratory analyses EGFR,kRAS mutations and other molecular markers in tumors of NSCLC patients(pts)treated with chemotherapy±erlotinib(TALENT).J Clin Oncol.23:16s:7028a.
Gervasini G,Garc(?)a-Mart(?)n E,Ladero JM,Pizarro R,Sastre J,Martinez C,Garc(?)a M,Diaz-Rubio M,Ag(?)ndez JA.(2007)Genetic variability in CYP3A4 and CYP3A5 in primary liver,gastric and colorectal cancer patients.BMC Cancer.2:118-125.
Guan ZZ,Zhang L,Li LY,Jiang GL,Liu XY,Chu DT,Zhao HY,Li W.(2005)Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small-cell lung cancer:a clinical trial.Ai Zheng.24:980-984.
Guidance for Industry Pharmacogenomic Data Submissions[http://www.fda.gov /cder /guidance /6400fhl.pdf]
Hajra KM,Liu JR.(2004)Apoptosome dysfunction in human cancer.Apoptosis.9:691-704.
Hirsch FR,Varella-Garcia M,Bunn PA Jr,Franklin WA,Dziadziuszko R,Thatcher N,Chang A,Parikh P,Pereira JR,Ciuleanu T,von Pawel J,Watkins C,Flannery A,Ellison G,Donald E,Knight L,Parums D,Botwood N,Holloway B.(2006)Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small cell lung cancer.J Clin Oncol.24:5034-5042.
Hirvonen A,Husgafvel-Pursiainen K,Anttila S,Karjalainen A,Sorsa M,Vainio H.(1992)Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.Pharmacogenetics.2:259-263.
Ho PK,Hawkins CJ.(2005)Mammalian initiator apoptotic caspases.FEBS J.272:5436-5453.
Huang QR,Morris D,Manolios N.(1997)Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas(CD95)gene.Mol Immunol.34:577-582.
Hung RJ,Boffetta P,Brockmoller J,Butkiewicz D,Cascorbi I,Clapper ML,Garte S,Haugen A,Hirvonen A,Anttila S,Kalina I,Le Marchand L,London SJ,Rannug A,Romkes M,Salagovic J,Schoket B,Gaspari L,Taioli E.(2003)CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers:a pooled analysis.Carcinogenesis.24:875-882.
Inoue A,Suzuki T,Fukuhara T,Maemondo M,Kimura Y,Morikawa N,Watanabe H,Saijo Y,Nukiwa T.(2006)Prospective phase Ⅱ study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.J Clin Oncol.24:3340-3346.
Jackman DM,Yeap BY,Sequist LV,Lindeman N,Holmes AJ,Joshi VA,Bell DW,Huberman MS,Halmos B,Rabin MS,Haber DA,Lynch TJ,Meyerson M, Johnson BE,J(a|¨)nne PA.(2006)Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res.12:3908-3914.
Jiang H.(2009)Overview of gefitinib in non-small cell lung cancer:an asian perspective.Jpn J Clin Oncol.39:137-150.
Kakiuchi S,Daigo Y,Ishikawa N,Furukawa C,Tsunoda T,Yano S,Nakagawa K,Tsuruo T,Kohno N,Fukuoka M,Sone S,Nakamura Y.(2004)Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib(Iressa,ZD1839).Hum Mol Genet.13:3029-3043.
Kawajiri K,Nakachi K,Imai K,Yoshii A,Shinoda N,Watanabe J.(1990)Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene.FEBS Lett.263:131-133.
Kelly K,Crowley J,Bunn PA Jr,Presant CA,Grevstad PK,Moinpour CM,Ramsey SD,Wozniak AJ,Weiss GR,Moore DF,Israel VK,Livingston RB,Gandara DR.(2001)Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a Southwest Oncology Group trial.J Clin Oncol.19:3210-3218.
Kiechle FL,Zhang X.(2002)Apoptosis:biochemical aspects and clinical implications.Clin Chim Acta.326:27-45.
Kim JG,Chae YS,Sohn SK,Moon JH,Ryoo HM,Bae SH,Kum Y,Jeon SW,Lim KH,Kang BM,Park IJ,Choi GS,Jun SH.(2009)Prostaglandin synthase 2/cyclooxygenase 2(PTGS2/COX2)8473T＞C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.Cancer Chemother Pharmacol.Feb 15.
Kim ES,Hirsch V,Mok T,Socinski MA,Gervais R,Wu YL,Li LY,Watkins CL,Sellers MV,Lowe ES,Sun Y,Liao ML,Osterlind K,Reck M,Armour AA,Shepherd FA,Lippman SM,Douillard JY.(2008)Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase Ⅲ trial.Lancet.372:1809-1818.
Koomagi R,Volm M.(1999)Expression of FAS(CD95/APO-1)and FAS ligand in lung cancer,its prognostic and predictive relevance.Int J Cancer.84:239-243.
Kris MG,Natale RB,Herbst RS,Lynch TJ Jr,Prager D,Belani CP,Schiller JH,Kelly K,Spiridonidis H,Sandler A,Albain KS,Cella D,Wolf MK,Averbuch SD,Ochs JJ,Kay AC.(2003)Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer.A randomized trial.J Am Med Assoc.290:2149-2158.
Landi MT,Bertazzi PA,Shields PG,Clark G,Lucier GW,Garte SJ,Cosma G,Caporaso NE.(1994)Association between CYP1A1 genotype,mRNA expression and enzymatic activity in humans.Pharmacogenetics.4:242-246.
Lee D,Kim S,Park K,Kim J,Lee J,Shin S,Kang J,Suh C,Ahn M,Ahn J.(2008)A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer(NSCLC)who have previously received platinum-based chemotherapy.J Clin Oncol.26(Suppl)(abstr 8025).
Lenferink AE,Pinkas-Kramarski R,van de Poll ML,van Vugt MJ,Klapper LN,Tzahar E,Waterman H,Sela M,van Zoelen EJ,Yarden Y.(1998)Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.EMBO J.17:3385-3397.
Li J,Zhao M,He P,Hidalgo M,Baker SD.(2007)Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes.Clin Cancer Res.13:3731-3737.
Ling YH,Lin R,Perez-Soler R.(2008)Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.Mol Pharmacol. 74:793-806.
刘炬,张雪梅,张湘茹,袁芃、徐兵河、林东昕。(2006)ERCC6 C6530G 单核苷酸多态与局限期小细胞肺癌患者生存相关。中国癌症杂志。16:943-947。
Loukola A,Chadha M,Penn SG,Rank D,Conti DV,Thompson D,Cicek M,Love B,Bivolarevic V,Yang Q,Jiang Y,Hanzel DK,Dains K,Paris PL,Casey G,Witte JS.(2004) Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1,CYP3A4,and SRD5A2.Eur J Hum Genet.12:321-332.
Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC,Settleman J,Haber DA.(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med.350:2129-2139.
Ma F,Sun T,Shi Y,Yu D,Tan W,Yang M,Wu C,Chu D,Sun Y,Xu B,Lin D.(2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.Lung Cancer,2009,Feb 5.
Marchetti A,Felicioni L,Buttitta F.(2006) Assessing EGFR mutations.N Engl J Med.354:526-528.
Maruyama R,Nishiwaki Y,Tamura T,Yamamoto N,Tsuboi M,Nakagawa K,Shinkai T,Negoro S,Imamura F,Eguchi K,Takeda K,Inoue A,Tomii K,Harada M,Masuda N,Jiang H,Itoh Y,Ichinose Y,Saijo N,Fukuoka M.(2008) Phase Ⅲstudy,V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.J Clin Oncol.26:4244-4252.
Masson LF,Sharp L,Cotton SC,Little J.(2005) Cytochrome P450 1A1 gene polymorphisms and risk of breast cancer:A HuGE review.Am J Epidemiol.161:901-915.
Mendelsohn J,Baselga J.(2000)The EGF receptor family as targets for cancer therapy.Oncogene.19:6550-6565.
Miller VA,Zakowski M,Riley GJ,Pao W,Ladanyi M,Tsao AS,Sandler A,Herbst R,Kris MG,Johnson DH.(2006)EGFR mutation and copy number,EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma(BAC):results of a prospective phase Ⅱ trial.J Clin Oncol.24:364s.
Mok T,Wu YL,Thongprasert S.(2008)Phase Ⅲ,randomised,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer.Ann Oncol.19(Suppl.8)(viiil,Abstract LBA2).
Mooney LV,Bell DA,Santella RM,Van Bennekum AM,Ottman R,Paik M,Blaner WS,Lucier GW,Covey L,Young TL,Cooper TB,Glassman AH,Perera FP.(1997)Contribution of genetic and nutritional factors to DNA damage in heavy smokers.Carcinogenesis.18:503-509.
Morita S,Hiroshima T,Hagiwara K.(2008)I-CAMP Study Group.Gefitinib combined survival analysis of the mutation positives from the prospective phase Ⅱ trials(I-CAMP).J Clin Oncol.6(Suppl.)(Abstract 8101).
Nambu Y,Hughes SJ,Rehemtulla A.(1998)Lack of cell surface FAS/APO-1 expression in pulmonary adenocarcinoma.J Clin Invest.101:1102-1110.
Normanno N,Campiglio M,De LA,Hamstra D,Orringer MB,Beer DG.(2002)Cooperative inhibitory effect of ZD1839(Iressa)in combination with trastuzumab(Herceptin)on human breast cancer cell growth.Ann Oncol.13:65-72.
Paez JG,Janne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H,FujⅡ Y,Eck MJ,Sellers WR,Johnson BE,Meyerson M.(2004)EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy.Science.304:1497-1500.
Pan JH,Han JX,Wu JM,Sheng LJ,Huang HN.(2007)CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.Acta Oncol.46:361-366.
Pao W,Wang TY,Riely GJ,Miller VA,Pan Q,Ladanyi M,Zakowski MF,Heelan RT,Kris MG,Varmus HE.(2005)KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PLoS Med.2:el 7.
Park JY,Lee WK,Jung DK,Choi JE,Park TI,Lee EB,Cho S,Park JY,Cha SI,Kim CH,Kam S,Jung TH,Jheon S.(2009)Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.Clin Cancer Res.15:1794-1800.
Parkin DM,Bray F,Ferlay J,Pisani P.(2005)Global cancer statistics,2002.CA Cancer J Clin.55:74-108.
Park K,Goto K.(2006)A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.Curr Med Res Opin.22:561-573.
Paz-Ares L,Sanchez JM,Garci'a-Velasco A,Massuti B,Lopez-Vivanco G,Provencio M,Montes A,Isla D,Amador ML,Rosell R,Spanish Lung Cancer Group.(2006)A prospective phase Ⅱ trial of erlotinib in advanced non-small cell lung cancer(NSCLC)patients(p)with mutations in the tyrosine kinase(TK)domain of the epidermal growth factor receptor(EGFR).J Clin Oncol,24(suppl):18s:7020a.
Perez-Soler R,Chachoua A,Hammond LA,Rowinsky EK,Huberman M,Karp D,Rigas J,Clark GM,Santabarbara P,Bonomi P.(2004)Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol.22:3238-3247.
Pham D,Kris MG,Riely GJ,Sarkaria IS,McDonough T,Chuai S,Venkatraman ES,
Miller VA,Ladanyi M,Pao W,Wilson RK,Singh B,Rusch VW.(2006)Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.J Clin Oncol.24:1700-1704 。
Piechocki MP,Yoo GH,Dibbley SK,Amjad EH,Lonardo F.(2006)Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.Int J Cancer.119:441-454.
Pirker R,Szczesna A,von Pawel J,Krzakowski M,Ramlau R,Park K,Gatzemeier U,Bajeta E,Emig M,Pereira JR.(2008)FLEX:A randomized multicenter,phase Ⅲ study of cetuximab in combination with cisplatin/vinorelbine(CV)versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer(NSCLC).J Clin Oncol.26:3
Raff M.(1998)Cell suicide for beginners.Nature.396:119-122.
Reed JC.(2000)Mechanisms of apoptosis.Am J Pathol.157:1415-1430.
Rho JK,Choi YJ,Ryoo BY,Na Ⅱ,Yang SH,Kim CH,Lee JC.(2007)p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.Cancer Res.67:1163-1169.
Riely GJ,Pao W,Pham D,Li AR,Rizvi N,Venkatraman ES,Zakowski MF,Kris MG,Ladanyi M,Miller VA.(2006)Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res.12:839-844.
Risch NJ.(2000)Searching for genetic determinants in the new millennium.Nature.405:847-856.
Sanchez-Cespedes M,Ahrendt SA,Piantadosi S,Rosell R,Monzo M,Wu L,Westra WH,Yang SC,Jen J,Sidransky D.(2001)Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.Cancer Res.61:1309-1313.
Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R, Johnson DH.(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med.355:2542-2550.
Sasaki H,Endo K,Takada M,Kawahara M,Tanaka H,Kitahara N,Matsumura A,Iuchi K,Kawaguchi T,Okuda K,Kawano O,Yukiue H,Yokoyama T,Yano M,Fujii Y.(2008)EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer.J Surg Res.148:260-263.
Schiller JH,Harrington D,Belani CP,Langer C,Sandler A,Krook J,Zhu J,Johnson DH;Eastern Cooperative Oncology Group.(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med.346:92-98.
Sequist LV,Joshi VA,Janne PA,Muzikansky A,Fidias P,Meyerson M,Haber DA,Kucherlapati R,Johnson BE,Lynch TJ.(2001)Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist.12:90-98.
Sequist LV,Martins RG,Spigel D,Grunberg SM,Spira A,Janne PA,Joshi VA,McCollum D,Evans TL,Muzikansky A,Kuhlmann GL,Han M,Goldberg JS,Settleman J,Iafrate AJ,Engelman JA,Haber DA,Johnson BE,Lynch TJ.(2008)First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations.J Clin Oncol.26:2442-2449.
Shigematsu H,Lin L,Takahashi T,Nomura M,Suzuki M,Wistuba Ⅱ,Fong KM,Lee H,Toyooka S,Shimizu N,Fujisawa T,Feng Z,Roth JA,Herz J,Minna JD,Gazdar AF.(2005)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst.97:339-346.
Smart J,Daly AK.(2000)Variation in induced CYPlAl levels:relationship to CYPlAl,Ah receptor and GSTM1 polymorphisms.Pharmacogenetics.10:11-24.
Song N,Tan W,Xing D,Lin D.(2001)CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking:a case-control study in China.Carcinogenesis.22:11-16.
Sugimura H,Wakai K,Genka K,Nagura K,Igarashi H,Nagayama K,Ohkawa A,Baba S,Morris BJ,Tsugane S,Ohno Y,Gao C,Li Z,Takezaki T,Tajima K,Iwamasa T.(1998)Association of Ile462Val(Exon 7)polymorphism of cytochrome P450 IAI with lung cancer in the Asian population:further evidence from a case-control study in Okinawa.Cancer Epidemiol Biomarkers Prev.7:413-417.
Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels[http://www.fda.gov:80/cder/genomics/ genomic_biomarkers_table.htm]
Taioli E,Gaspari L,Benhamou S,Boffetta P,Brockmoller J,Butkiewicz D,Cascorbi I,Clapper ML,Dolzan V,Haugen A,Hirvonen A,Husgafvel-Pursiainen K,Kalina I,Kremers P,Le Marchand L,London S,Rannug A,Romkes M,Schoket B,Seidegard J,Strange RC,Stucker I,To-Figueras J,Garte S.(2003)Polymorphisms in CYP1A1,GSTM1,GSTT1 and lung cancer below the age of 45 years.Int J Epidemiol.32:60-63.
Takano T,Ohe Y,Sakamoto H,Tsuta K,Matsuno Y,Tateishi U,Yamamoto S,Nokihara H,Yamamoto N,Sekine I,Kunitoh H,Shibata T,Sakiyama T,Yoshida T,Tamura T.(2005)Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.J Clin Oncol.23:6829-6837.
Tefre T,Ryberg D,Haugen A.(1991)Human CYP1A1(cytochrome P(1)450)gene:lack of association between the Mspl restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population.Pharmacogenetics.1:20-25.
Thatcher N,Chang A,Parikh P,Rodrigues Pereira J,Ciuleanu T,von Pawel J,Thongprasert S,Tan EH,Pemberton K,Archer V,Carroll K.(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer).Lancet.366:1527-1537.
Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG.(2000)New guidelines to evaluate the response to treatment in solid tumors.EuropeanOrganization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst.92:205-216.
Tsao M,Zhu C,Sakurada A,Zhang T,Whitehead M,Kamel-Reid S,Ding K,Seymour L,Shepherd F.(2006)An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer.J Clin Oncol.24:365s.
Tsao MS,Sakurada A,Cutz JC,Zhu CQ,Kamel-Reid S,Squire J,Lorimer I,Zhang T,Liu N,Daneshmand M,Marrano P,da Cunha Santos G,Lagarde A,Richardson F,Seymour L,Whitehead M,Ding K,Pater J,Shepherd FA.(2005)Erlotinib in lung cancer-molecular and clinical predictors of outcome.N Engl J Med.353:133-144.
Villaflor VM,Buckingham L,Gale M,Coon J,Mauer AM,Muzzafar T,Kaiser K,Shannon M,Morrison L,Bonomi P.(2006)EGFR mutations(muts),IHC and FISH status,and chromosome 7 gene copy number combined with pAkt expression as potential predictors of survival in non-small cell lung cancer(NSCLC)patients(pts)treated with gefitinib(GEF).J Clin Oncol.24:18s:7182a0
Vineis P,Bartsch H,Caporaso N,Harrington AM,Kadlubar FF,Landi MT,Malaveille C,Shields PQ Skipper P,Talaska G,et al.(1994)Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens.Nature.369:154-156.
Vineis P.(1997)Molecular epidemiology:low-dose carcinogens and genetic susceptibility.Int J Cancer.71:1-3.
Vineis R Veglia F,Benhamou S,Butkiewicz D,Cascorbi I,Clapper ML,Dolzan V,Haugen A,Hirvonen A,Ingelman-Sundberg M,Kihara M,Kiyohara C,Kremers P,Le Marchand L,Ohshima S,Pastorelli R,Rannug A,Romkes M,Schoket B,Shields P,Strange RC,Stucker I,Sugimura H,Garte S,Gaspari L,Taioli E.(2003)CYP1A1 T3801 C polymorphism and lung cancer:a pooled analysis of 2451 cases and 3358 controls.Int J Cancer.104:650-657.
Volm M,Koomagi R.(2008)Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.Br J Cancer.82:1747-1754.
Wang SE,Narasanna A,Perez-Torres M,Xiang B,Wu FY,Yang S,Carpenter G,Gazdar AF,Muthuswamy SK,Arteaga CL.(2006)HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Cancer Cell.10:25-38.
Whyatt RM,Bell DA,Jedrychowski W,Santella RM,Garte SJ,Cosma G,Manchester DK,Young TL,Cooper TB,Ottman R,Perera FP.(1998)Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype.Carcinogenesis.19:1389-1392.
Wilkinson GR.(2005)Drug metabolism and variability among patients in drug response.N Engl J Med.352:2211-2221.
Woodburn JR.(1999)The epidermal growth factor receptor and its inhibition in cancer therapy.Pharmacol Ther.82:241-250.
Wu J,Metz C,Xu X,Abe R,Gibson AW,Edberg JC,Cooke J,Xie F,Cooper GS,Kimberly RP.(2003)A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression:a candidate background gene in African American systemic lupus erythematosus patients.J Immunol.170:132-138.
Yang CH,Yu CJ,Shih JY,Chang YC,Hu FC,Tsai MC,Chen KY,Lin ZZ,Huang CJ,Shun CT,Huang CL,Bean J,Cheng AL,Pao W,Yang PC.(2008)Specific EGFR mutations predict treatment outcome of stage ⅢB/Ⅳ patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.J Clin Oncol.26:2745-2753.
Yang M,Sun T,Wang L,Yu D,Zhang X,Miao X,Liu J,Zhao D,Li H,Tan W,Lin D.(2008)Functional variants in cell death pathway genes and risk of pancreatic cancer.Clin Cancer Res.14:3230-3236.
Yoon KA,Park S,Hwangbo B,Shin HD,Cheong HS,Shin HR,Lee JS.(2007)Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.Carcinogenesis.28:1971-1977.
Zhang B,Sun T,Xue L,Han X,Zhang B,Lu N,Shi Y,Tan W,Zhou Y,Zhao D,Zhang X,Guo Y,Lin D.(2007)Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.Carcinogenesis.28:1067-1073.
Zhang X,Miao X,Sun T,Tan W,Qu S,Xiong P,Zhou Y,Lin D.(2005)Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.J Med Genet.42:479-484.
Zhou BB,Peyton M,He B,Liu C,Girard L,Caudler E,Lo Y,Baribaud F,Mikami I,Reguart N,Yang G,Li Y,Yao W,Vaddi K,Gazdar AF,Friedman SM,Jablons DM,Newton RC,Fridman JS,Minna JD,Scherle PA.(2006)Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.Cancer Cell.10:39-50.
Zimmerman KC,Bonzon C,Green DR.(2002)The machinery of programmed cell death.Pharmacol Ther.92:57-70.